- Global Pharma News & Resources

Antabio Awarded $4.4 Million from CARB-X for the Further Development of its New Treatment for Pseudomonas aeruginosa Infections in Cystic Fibrosis Patients

Labège, France, 2nd January 2020, Antabio SAS, the biopharmaceutical company focused on developing a broad pipeline of  antibacterial treatments against life threatening WHO critical priority pathogens, announces today that it has been awarded up to $4.4 million in a second tranche funding from CARB-X, the global non-profit partnership dedicated to tackling the global rising threat of drug-resistant bacteria. The funding is to support the development of Antabio’s novel small molecule candidate for the treatment of Pseudomonas aeruginosa infections in Cystic Fibrosis (CF) patients.

This new tranche, part of a CARB-X award announced in July 2017, will be used to advance Antabio’s Pseudomonas Elastase Inhibitor (PEi) program up to completion of non-GLP preclinical studies. The additional funding recognizes Antabio’s successful completion of project milestones during the first contractual period leading to the identification of a preclinical candidate.

Antabio’s innovative PEi program seeks to develop an inhaled product to be used as an adjunct to existing therapy and which will aim to reduce the severity of P. aeruginosa disease and enhance pathogen clearance by targeting the LasB elastase, a key virulence determinant that contributes to tissue damage and inflammation in infected CF lungs. Antabio believes the PEi product, with its novel target and groundbreaking mechanism of action, has the potential to significantly enhance the effectiveness of existing treatments for CF patients.

Cystic Fibrosis (CF) is a genetic condition leading to long-term infections and progressive lung damage. The majority (>80%) of adult CF patients have acute and chronic infections caused by the bacterium P. aeruginosa, which has adapted to resist immune clearance and conventional antibiotics, leading to treatment failure, chronic infection and recurrent acute exacerbations. P. aeruginosa is one of the most critical pathogens urgently requiring alternative treatment strategies, according to the World Health Organization (WHO).

Marc Lemonnier, Antabio’s CEO, commented, “We are very pleased by CARB-X’s continued financial support for our program focused on the development of our novel Pseudomonas elastase inhibitors. We believe that this program has the potential to deliver new molecules that will enhance the effects of the current antibiotics and improve the treatment of infections in CF patients.  Antabio is committed to developing new truly innovative treatment options that can address the growing global issue of antimicrobial resistance and which can deliver potentially significant life-saving clinical benefits to patients.

"CARB-X funds the best science and most promising research projects around the world to address drug resistance," said Erin Duffy, CARB-X’s Chief of R&D. "CARB-X's pipeline, which includes Antabio’s novel PEi approach to AMR, continues to expand with innovative antibiotics and prevention approaches. Our milestone-based funding is designed to recognize success in the progression of highly innovative programs, like those pursuing the urgently needed treatment of severe Pseudomonas aeruginosa infections. Congratulations to Antabio on the progress achieved to-date."

Editor Details

Related Links

Last Updated: 02-Jan-2020